FY2024 EPS Estimates for BrainsWay Lifted by Northland Capmk

BrainsWay Ltd. (NASDAQ:BWAY) – Equities research analysts at Northland Capmk upped their FY2024 earnings per share estimates for shares of BrainsWay in a research report issued on Tuesday, November 12th. Northland Capmk analyst C. Byrnes now anticipates that the company will post earnings per share of $0.06 for the year, up from their prior estimate of $0.05. The consensus estimate for BrainsWay’s current full-year earnings is $0.05 per share.

BrainsWay (NASDAQ:BWAY) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.03. The company had revenue of $10.50 million during the quarter, compared to the consensus estimate of $10.07 million. BrainsWay had a return on equity of 3.56% and a net margin of 3.88%. During the same quarter in the prior year, the firm earned ($0.01) EPS.

Several other equities analysts have also weighed in on BWAY. HC Wainwright restated a “buy” rating and set a $16.00 target price on shares of BrainsWay in a report on Monday, October 21st. Northland Securities raised their target price on BrainsWay from $11.00 to $12.50 and gave the company an “outperform” rating in a report on Thursday, October 3rd.

BrainsWay Trading Down 6.8 %

Shares of NASDAQ:BWAY opened at $9.04 on Thursday. BrainsWay has a 1 year low of $3.80 and a 1 year high of $10.98. The business has a fifty day simple moving average of $9.16 and a 200 day simple moving average of $7.44. The firm has a market cap of $150.79 million, a price-to-earnings ratio of 91.11 and a beta of 1.25.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of BWAY. Acadian Asset Management LLC raised its position in shares of BrainsWay by 48.1% during the 2nd quarter. Acadian Asset Management LLC now owns 259,787 shares of the company’s stock valued at $1,567,000 after acquiring an additional 84,371 shares during the last quarter. Good Life Advisors LLC raised its holdings in BrainsWay by 65.5% in the 3rd quarter. Good Life Advisors LLC now owns 55,800 shares of the company’s stock valued at $516,000 after acquiring an additional 22,080 shares during the period. Perritt Capital Management Inc bought a new position in BrainsWay in the 2nd quarter valued at about $121,000. Rhumbline Advisers raised its position in shares of BrainsWay by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 18,077 shares of the company’s stock valued at $110,000 after buying an additional 1,695 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in shares of BrainsWay in the 1st quarter valued at $60,000. 30.11% of the stock is owned by institutional investors and hedge funds.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.